The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases

Acta Oncol. 2009;48(6):927-31. doi: 10.1080/02841860902974167.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy
  • Carcinoma, Renal Cell / physiopathology*
  • Carcinoma, Renal Cell / secondary
  • Female
  • Humans
  • Indoles / therapeutic use*
  • Kidney Neoplasms / drug therapy
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / physiopathology*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / physiopathology*
  • Lung Neoplasms / secondary
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Nephrectomy
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pleural Neoplasms / drug therapy
  • Pleural Neoplasms / physiopathology*
  • Pleural Neoplasms / secondary
  • Pyridines / therapeutic use*
  • Pyrroles / therapeutic use*
  • Sorafenib
  • Sunitinib
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Indoles
  • Phenylurea Compounds
  • Pyridines
  • Pyrroles
  • Niacinamide
  • Sorafenib
  • Sunitinib